Amgen's $1.3 Bil. Acquisition Of Tularik Would Yield Two Late-Stage Oncologics

Tularik would broaden Amgen's oncology portfolio to small molecules with compounds for hepatocellular carcinoma, and esophageal and gastric cancers. The deal is one-tenth the size of Amgen's last acquisition – the $10 bil. Immunex purchase.